Onconetix, Inc., a pharmaceutical preparations company with a market capitalization of $4.48 million, has entered into a material definitive agreement and created a direct financial obligation ...

Onconetix, Inc., a pharmaceutical preparations company with a market capitalization of $4.48 million, has entered into a material definitive agreement and created a direct financial obligation, ...

Onconetix, Inc., a pharmaceutical company with a market capitalization of just $3.98 million, has received a notification from The Nasdaq Stock Market LLC indicating non-compliance with the ...

Should Onconetix fail to meet the minimum bid price by the end of the initial 180-day period, it may be eligible for an additional 180 days to regain compliance. This extension is contingent upon ...

Onconetix, Inc., a pharmaceutical company with a market capitalization of just $3.98 million, has received a notification from The Nasdaq Stock Market LLC indicating non-compliance with the minimum ...

06:17 EST Onconetix (ONCO) files to sell 50M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now ...

Cincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (the “Company”) announced that it received a letter from The Nasdaq Capital Market (“Nasdaq”) on December 6, 2024 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...